• Founded: 2018
  • Location: San Diego, CA
  • Employee range: 50 - 200
  • Clinical stage: RD
  • Therapy area: Immuno-oncology
  • Drug types: ONC, NEU
  • Lead product: Undisclosed
  • Product link:
  • Funding: $102M B Feb 2022; $35M A Jan 2021; $28M A Oct 2019
  • Investors: Column Group, DCVC Bio, M Ventures, CRV, Neotribe Ventures

job board

Short description:

Small Molecules Targeting E3 Ligase

Drug notes:

7* additional undisclosed programs RD multiple cancers, CNS condition, undisclosed

Long description:

Plexium is advancing developments in targeted protein degradation (TPD). By using their proprietary ultra-high-throughput cell-based (uHTS) screening technology, Plexium is detecting and designing monovalent protein degraders that can be used in many modalities. The assay directly measures degradation of multiple target proteins in disease-relevant environments to identify hit compounds. The uHTS screening is part of the larger Plexium Platform that combines genomic analysis, computational modeling and AI analytics to create their TPD drugs.The monovalent protein degraders overcome the limitations of current approaches and include the discovery of novel E3 ligases and new molecular glues. Plexium is creating a diverse pipeline that is currently in preclinical stages.


Director, Business Development
San Diego, CA|30 days ago
Senior Research Associate, Screening
San Diego, CA|36 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy